Rate My Professor Quentin Anstee

Professor Quentin M. Anstee serves as Pro-Vice-Chancellor of the Faculty of Medical Sciences and holds the Ruth & Lionel Jacobson Chair in Personalised Medicine at Newcastle University, formerly known as the University of Newcastle-upon-Tyne. He is Professor of Experimental Hepatology and Honorary Consultant Hepatologist at Freeman Hospital, part of the Newcastle upon Tyne NHS Foundation Trust. Anstee completed his BSc (Hons) 1st Class in Cell Pathology and Basic Medical Sciences at University College London in 1994, followed by MB BS with Distinction in Medicine in 1997, earning the First Prize in Medicine and the Philip Seth Belasco & Douglas Cree Prize. He obtained his PhD from Imperial College London in 2007, became a Member of the Royal College of Physicians (MRCP UK) in 2000, and was elected Fellow of the Royal College of Physicians (FRCP) in 2016. His medical training occurred at University College London, with postgraduate specialist training in Hepatology, Gastroenterology, and General Medicine at North-West London hospitals. From 2007 to 2010, he was Clinical Lecturer in Medicine and Hepatology at Imperial College London and St Mary's Hospital before joining Newcastle University in 2010, where he later served as Dean of Research & Innovation.

Anstee's research focuses on translational and clinical studies of Metabolic-dysfunction Associated Steatotic Liver Disease (MASLD, formerly Non-Alcoholic Fatty Liver Disease or NAFLD), investigating its pathophysiology, natural history, diagnosis, treatment, genetic and epigenetic modifiers of progression, biomarker development, and complications including cirrhosis and hepatocellular carcinoma. He is an NIHR Senior Investigator and named among the top 1% of scientists as a Web of Science Highly Cited Researcher. Key publications include 'A multisociety Delphi consensus statement on new fatty liver disease nomenclature' (2023), 'Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention' (2018), 'A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement' (2020), 'MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease' (2020), and 'Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis' (2013). His work advances understanding of liver disease progression and supports clinical trial designs for novel therapies.